Excess Death Estimates in Patients with End-Stage Renal Disease — United States, February–August 2020

• Published in: MMWR. Morbidity and mortality weekly report Vol. 70; no. 22; pp. 825 - 829
• Main Authors: Ziemba, Robert, Campbell, Kyle N, Yang, Tsu-Hsuan, Schaeffer, Sara Eve, Mayo, Kelly M, McGann, Paul, Quinn, Shalon, Roach, Jesse, Huff, Edwin D
• Format: Journal Article Newsletter
• Language: English
• Published: Atlanta U.S. Government Printing Office 04-06-2021; U.S. Center for Disease Control; Centers for Disease Control and Prevention
• Subjects: Care and treatment; Chronic kidney failure; Coronaviruses; COVID-19; Disease susceptibility; Disease transmission; End-stage renal disease; Epidemics; Estimates; Fatalities; Full Report; Health aspects; Hemodialysis; Kidney diseases; Kidney transplants; Maryland; Medical research; Medicare; Medicine, Experimental; Morbidity; Mortality; Pandemics; Patients; Public health; Severe acute respiratory syndrome coronavirus 2; Trends; Vaccination; Viral diseases; Maryland; New York; United States > US; Texas; New Jersey
• ISSN: 0149-2195; 1545-861X
• DOI: 10.15585/mmwr.mm7022e2

What is already known about this topic? Patients with end-stage renal disease (ESRD) are at increased risk for COVID-19–associated morbidity and mortality. What is added by this report? Based on the national trend in ESRD deaths during the first 7 months of the U.S. COVID-19 pandemic (February 1–August 31, 2020), an estimated 8.7–12.9 excess deaths per 1,000 patients or 6,953–10,316 excess deaths in a population of 798,611 U.S. ESRD patients occurred. What are the implications for public health practice? Geographic and temporal patterns of excess mortality, including those among persons with ESRD, should be considered during planning and implementation of interventions, such as COVID-19 vaccination, patient education, and rollout of infection control guidance and technical assistance.